Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2003
03/06/2003CA2465676A1 Compositions and techniques for localized therapy of restenosis
03/06/2003CA2458855A1 Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
03/06/2003CA2458854A1 Helicobacter pylori vaccination
03/06/2003CA2458849A1 Obesity related genes expressed at least in the hypothalamus, liver or pancreas
03/06/2003CA2458622A1 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
03/06/2003CA2458574A1 Reagents and methods for smooth muscle therapies
03/06/2003CA2458561A1 Yeast membrane protein expression system and its application in drug screening
03/06/2003CA2458445A1 Extracellular messengers
03/06/2003CA2458381A1 Transmembrane protein differentially expressed in cancer
03/06/2003CA2458219A1 Oral rinse for treatment or prevention of bacterial and fungal infection
03/06/2003CA2458217A1 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003CA2458132A1 Compositions comprising negatively charched phospholipids for treatment and/or prevention of macular degeneration and method for its manufacture
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2457979A1 A delivery system
03/06/2003CA2457976A1 Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
03/06/2003CA2457974A1 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
03/06/2003CA2457532A1 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003CA2457341A1 A new extended release oral dosage form
03/06/2003CA2456350A1 Novel imidazopyridine compounds with therapeutic effect
03/06/2003CA2455773A1 Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease
03/06/2003CA2442761A1 Drugs comprising chymase inhibitors and ace inhibitors as effective ingredients
03/05/2003EP1288299A2 TRNA synthetase
03/05/2003EP1288298A2 TRNA synthetase from Staphylococcus aureus
03/05/2003EP1288227A1 Coactivator of nuclear receptors
03/05/2003EP1287832A2 Use of leukemia inhibitory factor antagonist
03/05/2003EP1287830A1 Use of methioninase as an antitumor agent in anti-methionine chemotherapy
03/05/2003EP1287821A1 Multiparticulate formulations of atorvastatin calcium having a modulated rate of drug release
03/05/2003EP1287820A1 Aerosol compositions
03/05/2003EP1287817A1 Method of treating uterine leiomyomas and intravaginal drug delivery vehicle for use in such method
03/05/2003EP1287364A2 Diagnostics and therapeutics for macular degeneration-related disorders
03/05/2003EP1287363A2 Modulation of t-cell receptor interactions
03/05/2003EP1287355A2 Methods and compounds for influencing $g(b)3 integrin-dependent intracellular processes
03/05/2003EP1287354A2 Assay techniques based on growth stage dependent expression in c. elegans
03/05/2003EP1287353A2 Compound screens relating to insulin deficiency or insulin resistance
03/05/2003EP1287157A1 Protein markers for pharmaceuticals and related toxicity
03/05/2003EP1287141A2 Extracellular messengers
03/05/2003EP1287134A2 The human voltage-gated sodium channel beta-1a subunit and methods of use
03/05/2003EP1287132A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
03/05/2003EP1287131A2 Regulator of g protein signalling (rgs8)
03/05/2003EP1287130A2 Mammalian cytokine receptor subunit proteins, related reagents and methods
03/05/2003EP1287116A2 Neural progenitor cell populations
03/05/2003EP1287035A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
03/05/2003EP1287032A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
03/05/2003EP1287029A2 Compositions and methods for the therapy and diagnosis of colon cancer
03/05/2003EP1287020A2 Cancer diagnosis and assays for screening anti-cancer agents
03/05/2003EP1287019A1 Therapeutic approaches to diseases by suppression of the nurr subfamily of nuclear transcription factors
03/05/2003EP1286990A1 Stolonoxides
03/05/2003EP1286975A1 Biclyclic cyclohexylamines and their use as nmda receptor antagonists
03/05/2003EP1286974A2 Medicament for viral diseases
03/05/2003EP1286957A1 Diphenylmethane derivatives
03/05/2003EP1286702A2 HMG CoA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS
03/05/2003EP1286697A2 Method for selectively inhibiting ghrelin action
03/05/2003EP1286689A1 Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
03/05/2003EP1286684A2 Cxcr4 antagonist treatment of hematopoietic cells
03/05/2003EP1286682A1 Methods and compositions for inhibiting immunoglobulin-mediated--reperfusion injury
03/05/2003EP1286678A2 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer
03/05/2003EP1286674A1 Methods and compositions for potentiating cancer chemotherapeutic agents
03/05/2003EP1286673A2 Ligands of integrin receptors
03/05/2003EP1286668A2 Pharmaceutical combinations and their use in treating gastrointestinal disorders
03/05/2003EP1286664A2 Method of treating immune pathologies with low dose estrogen
03/05/2003EP1286663A2 Encapsulating a toxic core within a non-toxic region in an oral dosage form
03/05/2003EP1286661A2 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
03/05/2003EP1286659A2 Macromolecular drug complexes and compositions containing the same
03/05/2003EP1286657A1 Nasal ointment based on white petroleum jelly
03/05/2003EP1286653A1 Composition containing at least one aryl oxime and at least one active substance for treating acne and the use thereof
03/05/2003EP1115406A4 Sustained release, and comfortable ophthalmic composition and method for ocular therapy
03/05/2003EP1084569B1 Androgens in combination with gestagens for compensating for a testosterone deficiency in men while simultaneously protecting the prostate
03/05/2003EP0892633B1 Use of inhibitors of the activity of retinoic acid for treating sensitive skin and/or acute damage induced by uv radiation
03/05/2003EP0869807B1 Use of a medicament and use of mixture of substances to produce a medicament
03/05/2003EP0845034B1 peptide having pronociceptive properties
03/05/2003EP0830143B1 Use of leukemia inhibitory factor and endothelin antagonists
03/05/2003EP0782441B1 Pharmaceutical control of inflammation
03/05/2003EP0754060B1 New combination of a beta-receptor blocker and a local anaesthetic
03/05/2003EP0656952B1 Cationic peptides and method for production
03/05/2003CN1401001A 5HT3 receptors of nematodes, polynucleotide molecules encoding same, and antagonists thereof
03/05/2003CN1400909A Pharmaceutical composition
03/05/2003CN1400908A Combinations comprising dipeptidylpepidase IV inhibitors and antidiabetic agents
03/05/2003CN1400906A Treatment of congestive heart failure by pretreated autologous blood
03/05/2003CN1400904A Selective estrogen receptor modulators in combination with estrogens
03/05/2003CN1400903A Novel combination of non sedative anti histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjuncitivitis
03/05/2003CN1400902A Oral formulation comprising an inhibitor compound of the ileal bile transport and on HMG CO-A reductase inhibitor
03/05/2003CN1400896A Ibuprofen containing active agent preparation
03/05/2003CN1102410C Mupirocin calcium salt emulsifiable paste composition
03/05/2003CN1102386C Combination of 5-HT uptake inhibitor with selective 5-HT1A antagonist
03/05/2003CN1102382C Preparation and methods for the treatment of T cell mediated diseases
03/05/2003CA2356438A1 Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers
03/04/2003US6528637 Fatty acid synthase mRNA binding protein
03/04/2003US6528633 Cyclin-selective ubiquitin carrier polypeptides
03/04/2003US6528530 Side effect reduction; mainly the D-threo stereoisomer of a phenidate
03/04/2003US6528521 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
03/04/2003US6528520 Method of treating the syndrome of coronary heart disease risk factors in humans
03/04/2003US6528518 Treatment of depression with kappa receptor antagonists
03/04/2003US6528516 Methods for reducing intraocular pressure using A3 adenosine receptor antagonists
03/04/2003US6528515 Beta-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (beta -FTC) and penciclovir
03/04/2003US6528511 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
03/04/2003US6528509 Pyrazole compositions useful as inhibitors of ERK
03/04/2003US6528493 Modulating activity of endogenous protein
03/04/2003US6528294 To effect protein phosphorylation; for use in diagnosis and therapy
03/04/2003US6528271 Drug screening
03/04/2003US6528270 Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
1 ... 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 ... 1151